Michael Blake Streiff, MD - Johns Hopkins Outpatient Center

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation.Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health.Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy.Dr. DeZerns principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZerns goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment.

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia.Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology.He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023.

Dr. B. Douglas Smith is an Oncologist in Baltimore caring for patients with leukemias and other blood and bone marrow disorders and he is recognized nationally as an expert in the care of patients with these disorders and as a leader in novel therapeutics for these conditions. Dr. Smith serves as the Co-Director of Clinical Research Operations for the Division of Hematologic Malignancies and helps to manage the Division’s clinical research trials.Dr. Smith received his undergraduate degree in Biology from Lafayette College (Easton, PA), earned his M.D. at the Medical College of Pennsylvania (Philadelphia, PA), completed his Residency at Strong Memorial Hospital of the University of Rochester (Rochester, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Smith joined the Johns Hopkins faculty in 1998 at the completion of his training.His main research interests include drug development for patients with AML, CML, and MDS and he serves as Co-Investigator for the Oncology Center’s UM1 (early phase drug development) Grant. The Leukemia Program’s clinical trials portfolio has included trials for each of the 8 newly FDA-approved drugs for acute leukemia in the past 2 years. Dr. Smith has a passion for teaching trainees and has served on the Fellowship Executive Committee since 2010 focusing on the program’s educational platforms. He has won numerous teaching awards in both the Department of Oncology and the Department of Medicine multiple times, and he has a track record of mentoring fellows pursuing clinical-translational research and clinician-educator pathways. In 2020, Dr. Smith was awarded membership in the prestigious Miller Coulson Academy for Excellence in Clinical Care.He is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research. He has served on the National Comprehensive Cancer Network guideline panel for CML since 2001 and previously served on the AML panel from 2001-2015. Dr. Smith has extensive experience in the regulatory aspects of drug development and he currently serves as the Chair of the Johns Hopkins Institutional Review Board #2.